Evidence map›Paper›PMID 37867237›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT.

Jianing Tang, Guo Long, Kuan Hu, Desheng Xiao, Shuang Liu, Liang Xiao, Ledu Zhou, Yongguang Tao

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. The value of targeting CXCR4 withEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Jianing TangDepartment of Liver Surgery, Xiangya Hospital, Central South University, 110 Xiangya Road, Changsha, Hunan, 410078, China.
Guo LongDepartment of Liver Surgery, Xiangya Hospital, Central South University, 110 Xiangya Road, Changsha, Hunan, 410078, China.
Kuan HuDepartment of Liver Surgery, Xiangya Hospital, Central South University, 110 Xiangya Road, Changsha, Hunan, 410078, China.
Desheng XiaoDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410078, China.
Shuang LiuDepartment of Oncology, Institute of Medical Sciences, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410078, China.
Liang XiaoDepartment of Liver Surgery, Xiangya Hospital, Central South University, 110 Xiangya Road, Changsha, Hunan, 410078, China.
Ledu ZhouDepartment of Liver Surgery, Xiangya Hospital, Central South University, 110 Xiangya Road, Changsha, Hunan, 410078, China.
Yongguang TaoDepartment of Pathology, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Xiangya Hospital, Central South University, 110 Xiangya Road, Changsha, Hunan, 410078, China.ORCID 0000-0003-2354-5321
Central South University · CN

Funding

Central South University Research Programme of Advanced Interdisciplinary Studies 2023QYJC030Hunan Provincial Key Area R&D Programs 2021SK2013National Natural Science Foundation of China 81772927National Natural Science Foundation of China 81874139National Natural Science Foundation of China 82072594National Natural Science Foundation of China 82073097National Natural Science Foundation of China 82073136National Natural Science Foundation of China 82203160Natural Science Foundation of Hunan Province 2022JJ40815Postdoctoral Research Foundation of China 2022M713531Science and Technology Innovation Program of Hunan Province 2022RC3072
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a lethal and aggressive human malignancy. The present study examins the anti-tumor effects of deubiquitylating enzymes (DUB) inhibitors in HCC. It is found that the inhibitor of ubiquitin specific peptidase 8 (USP8) and DUB-IN-3 shows the most effective anti-cancer responses. Targeting USP8 inhibits the proliferation of HCC and induces cell ferroptosis. In vivo xenograft and metastasis experiments indicate that inhibition of USP8 suppresses tumor growth and lung metastasis. DUB-IN-3 treatment or USP8 depletion decrease intracellular cystine levels and glutathione biosynthesis while increasing the accumulation of reactive oxygen species (ROS). Mechanistical studies reveal that USP8 stabilizes O-GlcNAc transferase (OGT) via inhibiting K48-specific poly-ubiquitination process on OGT protein at K117 site, and STE20-like kinase (SLK)-mediated S716 phosphorylation of USP8 is required for the interaction with OGT. Most importantly, OGT O-GlcNAcylates solute carrier family 7, member 11 (SLC7A11) at Ser26 in HCC cells, which is essential for SLC7A11 to import the cystine from the extracellular environment. Collectively, this study demonstrates that pharmacological inhibition or knockout of USP8 can inhibit the progression of HCC and induce ferroptosis via decreasing the stability of OGT, which imposes a great challenge that targeting of USP8 is a potential approach for HCC treatment.

Indexed as

Carcinoma, HepatocellularFerroptosisLiver NeoplasmsAmino Acid Transport System y+CystineEndopeptidasesEndosomal Sorting Complexes Required for TransportHumansN-AcetylglucosaminyltransferasesUbiquitin ThiolesteraseAmino Acid Transport System y+CystineEndopeptidasesEndosomal Sorting Complexes Required for TransportN-AcetylglucosaminyltransferasesO-GlcNAc transferaseSLC7A11 protein, humanUbiquitin ThiolesteraseUSP8 protein, humandeubiquitylationferroptosisO-GlcNAcylationOGTUSP8

Identifiers

PMID37867237
PMCPMC10667802
OpenAlexW4387866149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.